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Phillips Kirk Labor, MD, Jeffrey Whitman, MD, Harvey Carter, MD, Michael Colvard, MD,
Phillip J. Buckhurst, PhD, Omid Khodai, OD, David Mittleman, MD, Gregg Feinerman, MDRS an
ElsevPURPOSE: To evaluate the safety and effectiveness of the Trulign toric intraocular lens (IOL) in
adults with cataract.
SETTING: Eight private practices in the United States and 1 in Canada.
DESIGN: Prospective randomized single-masked multicenter study.
METHODS: A toric IOL (1.25 D, 2.00 D, or 2.75 D, determined by a toric calculator) was implanted in
eligible patients with age-related cataract requiring a 16.00 to 27.00 diopter (D) spherical IOL power
and with a predicted postoperative astigmatism of 0.83 to 2.50 D. Eyes within the lowest cylinder
range (predicted postoperative astigmatism 0.83 to 1.32 D) were randomized in a 1:1 ratio between
the 1.25 D toric IOL group and the nontoric accommodating IOL (Crystalens) control group.
RESULTS: The toric 1.25 D group had a statistically significantly greater percentage reduction in abso-
lute cylinder (P < .001) and uncorrected distance visual acuity (PZ .002) than the control group at the
120- to 180-day visit. The mean monocular uncorrected vision at distance, intermediate, and near was
20/25, 20/22, and 20/39, respectively, with the 1.25 D, 2.00 D, and 2.75 D toric IOLs in aggregate (toric
group). In addition, 96.1% of patients (123/128) had 5.0 degrees or less absolute IOL rotation
postoperatively. Regarding safety, the endpoints for preservation of corrected visual acuity and the
incidence of complications and adverse events were met.
CONCLUSION: The toric IOL was safe and effective in reducing the effects of preoperative corneal
astigmatism and provided excellent uncorrected distance and intermediate vision and functional
near vision.
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J Cataract Refract Surg 2015; 41:295–305 Q 2015 ASCRS and ESCRSIt has been estimated that more than 1.0 diopter (D) of
preexisting corneal astigmatism occurs in 36% to 39%of
patients with cataract and more than 1.5 D of pre-
existing corneal astigmatism occurs in 15% to 22% of
patients with cataract.1–4 The visual outcome after
cataract surgery can be improved if preexisting corneal
astigmatism is corrected. Toric intraocular lenses (IOLs)
were conceived with the intent of providing greater
predictability and reversibility over keratorefractived ESCRS
ier Inc.procedures. The use of toric IOLs also mitigates some
disadvantages and side effects of incisional astigmatic
correction, such as varied wound healing, corneal
denervation, corneal perforation, infection, wound
gape, and decreased spectacle-corrected vision result-
ing from irregular astigmatism.5–8 Similarly, it elimi-
nates some limitations and side effects of excimer
laser correction of astigmatism, such as corneal haze,
dry eye, regression, and diffuse lamellar keratitis.9http://dx.doi.org/10.1016/j.jcrs.2014.05.043 295
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296 SAFETY AND EFFECTIVENESS OF A NEW TORIC PRESBYOPIA-CORRECTING PC SILICONE IOLThis study describes the clinical experience with a
new toric posterior chamber IOL, the Trulign (Bausch
& Lomb). The IOL is intended for primary implanta-
tion in the capsular bag for the visual correction of
aphakia and postoperative refractive astigmatism
secondary to removal of a cataractous lens in adults
with or without presbyopia who desire a reduction
in residual refractive cylinder with increased spectacle
independence and improved uncorrected near, inter-
mediate, and distance vision. This toric IOL has rectan-
gular hinged haptics with polyimide loops. These
loops help stabilize the IOL in the capsular bag and
have indicators to remind the surgeon that it is round
to the right to help ensure proper positioning. The IOL
has a single focal point (it does not split light between
multiple foci) and is designed to neither adversely
affect contrast sensitivity nor cause glare or halos.10--12
The objective of this study was to evaluate the safety
and effectiveness of the Trulign toric IOL in patients
having cataract extraction and IOL placement.
PATIENTS AND METHODSStudy Design and PatientsThis prospective randomized single-masked monocular
study was performed at 8 sites throughout the United States
and 1 site in Canada (clinical trial registration numberSubmitted: January 28, 2014.
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J CATARACT REFRACT SURG - VNCT01140477A). All patients provided written informed
consent after receiving an explanation of the purpose of the
study and the associated risks and benefits. Institutional re-
view board approval was obtained at each study site. The
study adhered to the tenets of the Declaration of Helsinki,
U.S. Food and Drug Administration (FDA) regulations,
and International Conference on Harmonization guidelines.
After a baseline preoperative examination, patients who
were eligible to receive a 1.25 D toric power IOL were ran-
domized to receive the Trulign toric IOL (model AT50 T or
AT52 T) (toric group) or nontoric Crystalens accommodating
IOL (model AT50SE or AT52SE, Bausch & Lomb) (nontoric
group). Each investigator was to contribute a minimum of
20 patients with toric IOLs; however, no investigator could
contribute more than 25% of the total toric IOL study enroll-
ment. Patients were evaluated postoperatively at scheduled
visits up to 330 to 420 days postoperatively. Patients were
masked to treatment assignment.
The study included patients who met the following
criteria: 18 years or older, had age-related cataract (cortical,
nuclear, subcapsular, or combination) that was considered
amenable to treatment with standard phacoemulsification/
extracapsular cataract extraction, scheduled for primary
IOL implantation for the correction of aphakia after contin-
uous curvilinear anterior capsulotomy and phacoemulsifica-
tion cataract extraction, required an IOL power from 16.00 to
27.00 D, had predicted postoperative corneal astigmatism
between 0.83 D and 2.50 D (determined by a toric calculator),
had a potential corrected distance visual acuity (CDVA) of
20/32 or better in the operated eye on potential visual acuity
meter testing, and had a CDVA of 20/40 or worse with or
without a glare source.
Exclusion criteria were previous corneal pathology poten-
tially affecting topography; anterior segment pathology for
which extracapsular/phacoemulsification cataract surgery
would have been contraindicated (eg, chronic uveitis, iritis,
iridocyclitis, rubeosis iridis, clinically significant corneal dys-
trophy, Fuchs dystrophy, anterior membrane dystrophy);
diagnosis of degenerative visual disorders that would cause
potential acuity losses to 20/32 or worse; conditions associ-
ated with an increased risk for zonular rupture; corneal
inflammation or edema (including keratitis, keratoconjuncti-
vitis, and keratouveitis); unable to achieve pupil dilation of
5.0 mm; uncontrolled glaucoma; previous retinal detach-
ment; diabetic retinopathy; previous corneal surgery in the
operative eye; rubella; bilateral congenital, traumatic, or
complicated cataract; marked microphthalmos or aniridia;
irregular corneal astigmatism, amblyopia; significant retinal
pigment or epithelium/macular changes; iris or chorio-
retinal neovascularization; optic atrophy; chronic use of
systemic steroids or immunosuppressive medications; and
a significant difference between corneal astigmatism
measured with partial coherence interferometry (PCI) (IOL-
Master, Carl ZeissMeditec AG) and axial topography (vector
difference between the 2 instruments!0.5 D).Intraocular LensesThe Trulign toric IOL is an astigmatism-correcting silicone
multipiece IOL (model AT-50T or AT-52T) (Figure 1) and is a
toric modification of the parent Crystalens. The plate haptics
are hinged adjacent to the optic and have small looped poly-
imide haptics. The overall length (loop tip to tip) of model
AT-50T is 11.5 mm, and the overall length (loop tip to tip)
of model AT-52T is 12.0 mm. The optic diameter is 5.0 mm,OL 41, FEBRUARY 2015
Figure 1. Schematic of the toric IOL.
297SAFETY AND EFFECTIVENESS OF A NEW TORIC PRESBYOPIA-CORRECTING PC SILICONE IOLand the recommended A-constant is 119.0. The toric IOL is
intended for placement in the capsular bag only. It has a
spherical front (anterior) surface and a toric back (posterior)
surface. Twomarks on the peripheral anterior optical surface
aid in proper alignment of the IOL; the lines indicate the flat
axis of the toric IOL. The available spherical equivalent (SE)
powers range fromC16.00 toC27.00 D in 0.50 D increments
with cylindrical powers at the lens plane of 1.25 D, 2.00 D,
and 2.75 D (estimated cylinder power at the corneal plane
0.83 D, 1.33 D, and 1.83 D, respectively). The flattest meri-
dian is along the long axis of the IOL.
The control was the Crystalens silicone multipiece accom-
modating IOL (model AT-50SE or AT-52SE). It has a modi-
fied platehaptic intended for placement in the capsular bag
only. The plate haptics are hinged to the optic and have small
looped polyimide haptics. The overall length (loop tip to tip)
of model AT-50SE is 11.5 mm, while the overall length (loop
tip to tip) ofmodel AT-52SE is 12.0mm. Bothmodels have an
optic diameter of 5.0 mm. The available SE powers range
from C16.00 to C16.50 D for the AT-52SE and C17.00 to
C27.00 D for the AT-50SE in 0.50 D increments. The recom-
mended A-constant for the control IOL is 119.0.Preoperative AssessmentWithin 90 days of surgery, baseline examinations,
including CDVA, intraocular pressure (IOP), and slitlamp
assessment, were performed. In addition, keratometry,
topography, axial length, and anterior chamber depth were
measured to determine the power of the IOL to be im-
planted. The Trulign Toric CalculatorB was used to calculate
the predicted postoperative corneal astigmatism using pre-
operative keratometry, phacoemulsification/insertion inci-
sion location, and the predicted magnitude of surgically
induced astigmatism (SIA) inputs from the investigator. A
fixed SIA value of 0.50 D was used in the toric calculator
for all patients in the study. The calculator determined the
toric IOL cylinder power needed and placement orientation
to best correct the patient's predicted postoperative corneal
astigmatism. The axis of placementwas identified as follows:
Immediately before surgery with the patient seated at theJ CATARACT REFRACT SURG - Vslitlamp, the patient's anesthetized dilated operative eye
was marked using the orientation of the slit beam rotated
according to the degree scale and using a marking instru-
ment of the surgeon's preference.Surgical TechniqueSurgeons used standard microsurgical techniques with
the following specifications: (1) To prevent forward vaulting
of the optic, an incision width no greater than 3.0 mm for the
AT-50T was recommended with a paracentesis approxi-
mately 1.5 mm long. (2) A multiplane incision was used to
ensure that it was watertight at the close of the case.
(3) The incision was placed at the preoperative keratometric
steep axis in all eyes. (4) The anterior chamber was entered
through the incision opening, and a cohesive ophthalmic vis-
cosurgical device (OVD) (surgeon's preference) was used to
fill the anterior chamber. (5) An anterior, round capsulo-
rhexis of 5.5 mm to 6.0 mmwas created to allow the anterior
capsule to cover the plate haptics while keeping the optic
free. (6) The cataract was extracted by phacoemulsification.
After the IOL was inserted, alignment was confirmed by
ensuring the markings on the IOL were aligned with the
placement markings on the cornea. Once the IOL was
aligned and vaulted posteriorly in the capsule, all OVD ante-
rior and posterior to the IOL was removed to prevent IOL
rotation. Before thewoundwas closed, a final checkwas per-
formed to ensure the axis was correctly aligned. Immediately
after surgery while the pupil was still dilated, a digital image
showing the IOL axismarks, optic edge, and scleral–conjunc-
tival blood vessels was recorded at 10 magnification using
image-capturing equipment (Haag Streit BD900 slitlamps
with CM900 digital cameras). The IOL and scleral–conjunc-
tival blood vessels were also imaged at regular intervals
over the course of the study after the pupil was dilated
with tropicamide 1.0% and phenylephrine 2.5%. The rota-
tional stability of the IOL was determined by analyzing the
postoperative IOL images, and any torsion of the eye was ac-
counted for using scleral–conjunctival landmarks.13,14Postoperative AssessmentPostoperatively, patients had a complete ophthalmic ex-
amination at regular intervals per the study visit schedule
as follows: visit 1 (1 to 2 days postoperatively), visit 2 (7
to 14 days postoperatively), visit 3 (30 to 60 days postoper-
atively), visit 4 (120 to 180 days postoperatively), visit 5 (245
to 301 days postoperatively), and visit 6 (330 to 420 days
postoperatively). Postoperative assessments included
manifest refraction (autorefraction was not permitted),
uncorrected distance visual acuity (UDVA), uncorrected
intermediate visual acuity (UIVA) measured at 80 cm, un-
corrected near visual acuity (UNVA) measured at 40 cm,
CDVA with glare, distance-corrected intermediate visual
acuity (DCIVA) measured at 80 cm, distance-corrected
near visual acuity (DCNVA) measured at 40 cm, corrected
near visual acuity measured at 40 cm, and cycloplegic
refraction using cyclopentolate 1.0%. The manifest refrac-
tion spherical equivalent (MRSE) was calculated as the
value of the sphere plus one half the value of the cylinder.
All visual acuities were recorded using the Optec 6500/
6500P Vision Tester (Stereo Optical Co.). In addition, the
incidence of adverse events, slitlamp results (corneal stro-
mal edema and anterior chamber aqueous cell and flare),
IOP, fundus examination, keratometry with PCI, corneal
topography, IOL rotational stability, and visualOL 41, FEBRUARY 2015
Table 1. Percentage reduction in absolute cylinder expressed as a percentage of the intended reduction in cylinder at the 120- to 180-day
postoperative visit.
Statistic
Nontoric IOL
(nZ 68)
Toric 1.25 D IOL
(nZ 74)
Toric 2.00 D IOL
(nZ 39)
Toric 1.75 D IOL
(nZ 21)
All Toric IOLs
(nZ 134)
Mean (%)G SD 46.5G 43.8 79.9G 31.8 88.0G 27.1 97.4G 19.2 85.0G 29.3
95% CI (%) 35.9, 57.1 72.5, 87.2 79.2, 96.7 88.7, 106.1 80.0, 90.0
P value d !.001 d d d
CIZ confidence interval; IOLZ intraocular lens
*Percentage reduction in absolute cylinder is defined as the difference between the postoperative magnitude of the subjective manifest refractive cylinder (con-
verted to the corneal plane) and the preoperative magnitude of the keratometric cylinder, divided by the intended reduction in cylinder, expressed as a per-
centage. The intended reduction in cylinder is the difference between the intended magnitude of the postoperative manifest refractive cylinder (converted to
the corneal plane), presuming toric IOL implantation, and the magnitude of the preoperative keratometric cylinder.
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sessed. Intraocular lens tilt was assessed using the method
described by Guyton et al.15Statistical AnalysisA sample size of at least 65 eyes in each group was
required to provide 90% power to detect a clinically signif-
icant difference in the percentage reduction in cylinder be-
tween eyes with the lowest IOL cylinder and eyes with the
nontoric IOL (control).16 The efficacy analyses included all
patients who had implantation of a study IOL (toric or
nontoric), whose IOL was not repositioned, and who had
no major protocol deviations (effectiveness cohort). The
safety analyses included all patients who had surgery for
the implantation of a study IOL (toric or nontoric),
whether a study IOL was implanted or not (safety cohort).
Two patients who were discontinued because of intraoper-
ative surgical complications and who therefore did not
receive a study or a control IOL were excluded from all
analyses.
The primary analysis occurred was when IOL rotational
stability was achieved, which was at the 120- to 180-day
visit. Vector analysis was used to calculate the SIA in the
effectiveness cohort at the 120- to 180-day visit. The SIA is
defined as the vector difference between the baseline and
the postoperative keratometric astigmatism vectors.
Continuous measures were described by the mean, stan-
dard deviation, minimum, and maximum. Categorical
measures were summarized using frequencies and percent-
ages. The primary efficacy endpoint was a comparison of
the reduction in cylinder between the low-cylinder toric
1.25 D group and the nontoric group at the time rotational
stability was achieved (120- to 180-day visit). The intended
reduction in cylinder was computed under the assumption
that a toric IOL would be implanted. Analysis of the per-
centage cylinder reduction (defined in the footnote in
Table 1) included continuous summary statistics, a 95%
confidence interval (CI) around the mean, and a 2-sample
1-sided t test assuming unequal variances to test the alter-
native hypothesis that the toric 1.25 D IOL yielded a greater
reduction in absolute cylinder than the control nontoric
IOL. Visual acuities were compared using 2-sided asymp-
totic Wilcoxon-Mann-Whitney rank-sum tests with conti-
nuity correction. Confidence intervals for percentages
were exact (Clopper-Pearson) binomial CIs. The mean
Snellen (feet) denominators were computed as 20 times
the common antilogarithm of the mean logMAR acuity
rounded to the nearest integer.J CATARACT REFRACT SURG - VRESULTSDisposition and Baseline CharacteristicsOf the patients, 229 were enrolled at 8 investigational
sites in the U.S. and 9 were enrolled at 1 site in Canada.
Twelve patients (5.2%) were excluded from the study
after IOL implantation. Of these, 4 (1.7%) were lost to
follow-up, 5 (2.2%)withdrew consent, 1 (0.4%) required
IOL explantation, and 2 (0.9%) died. In addition, 2 pa-
tients (0.9%) were excluded before IOL implantation
because of surgical complications. Of the 19 patients
excluded from the effectiveness cohort, 2 did not have
an IOL implanted and 17 had major protocol devia-
tions. Therefore, 210 patientswere included in the effec-
tiveness cohort, 138 patients in the toric group (75 with
a 1.25 D toric IOL; 40 with a 2.00 D toric IOL; 23 with a
2.75 D toric IOL) and 72 patients in the nontoric group.
Patients in the toric group and patients in the
nontoric group had similar demographics; 52.9% of
patients (81/153) in the toric group and 55.3%
(42/76) in the nontoric group were women. The
mean age was 70.1 years G 9.0 (SD) (range 48 to
89 years) in the toric group and 69.8G 9.2 years (range
47 to 89 years) in the nontoric group. The mean IOL SE
was 20.51G 2.26 D and 20.57G 2.29 D, respectively.Reduction in CylinderdPrimary EfficacyTable 1 shows the percentage reduction in absolute
cylinder expressed as a percentage of the intended
reduction in cylinder. The toric 1.25 D group had a
statistically significantly greater mean percentage
reduction in absolute cylinder than the nontoric group
(P! .001). Figure 2 compares the incidence (percentage
of study eyes) and magnitude (stratified by 0.00 D,%
0.50 D,%1.00 D,%1.50 D,%2.00 D, and O2.00 D) of
residual refractive cylinder at the 120- to 180-day visit
between the toric 1.25 D group and the nontoric group.
A greater percentage of eyes in the toric 1.25 D group
than in the nontoric group had a cumulative residual
cylinder of 1.00 D or less. Table 2 shows the percentage
of eyeswith a reduction in cylinderwithinG0.50D andOL 41, FEBRUARY 2015
Figure 2.Cumulative residual cylinder in the toric 1.25Dgroupand the
nontoric group at the 120- to 180-day visit (IOLZ intraocular lens).
Table 2. Eyes with a reduction in cylinder withinG0.50 D and
G1.00 D of the intended at the 120- to 180-day postoperative
visit.
Parameter Nontoric (nZ 72) All Toric (nZ 138)
WithinG0.50 D
of intended
Eyes, n (%) 30 (44.1) 105 (78.4)
95% CI (%) 32.1, 56.7 70.4, 85.0
WithinG1.00 D
of Intended
Eyes, n (%) 49 (72.1) 128 (95.5)
95% CI (%) 59.9, 82.3 90.5, 98.3
CIZ confidence interval
299SAFETY AND EFFECTIVENESS OF A NEW TORIC PRESBYOPIA-CORRECTING PC SILICONE IOLG1.00 D of the intended. The percentage of patients
withinG0.50 D andG1.00 D of the intended reduction
was greater in the all-diopter toric group than in the
nontoric group.Visual AcuityTable 3 shows the mean monocular UDVA, UIVA,
and UNVA at the 120- to 180-day visit. The mean
UDVA was statistically significantly better in the toric
1.25 D group than in the nontoric group (PZ .002) and
the all-diopter toric group (P ! .001). There were no
statistically significant differences in UIVA or UNVA
between the groups. At the 120- to 180-day visit,
135/138 (97.8%) in the all-diopter toric group had a
UDVA and UIVA of 20/40 or better and 97 (70.1%)
had UNVA of 20/40 or better (Figure 3).Table 3. Mean UDVA, UIVA, and UNVA at the 120- to 180-day postop
Parameter
Nontoric Control
(nZ 72)
Toric 1.25 D
(nZ 74)
UDVA
Mean Snellen 20/31 20/25
Mean logMARG SD 0.189G 0.181 0.099G 0.140
UIVA
Mean Snellen 20/23 20/22
Mean logMARG SD 0.069G 0.153 0.044G 0.116
UNVA
Mean Snellen 20/39 20/38
Mean logMARG SD 0.286G 0.137 0.284G 0.155
UDVAZ uncorrected distance visual acuity; UIVAZ uncorrected intermediate v
J CATARACT REFRACT SURG - VFor DCIVA at 32 inches (80 cm), DCNVA at 16 in-
ches (40 cm), andDCNVAwith addition (add) at 16 in-
ches (40 cm), no statistically significant differences
were found between the all-diopter toric group and
the nontoric group at the 120- to 180-day visit
(Table 4). Themean required addwas not significantly
different between the all-diopter toric group and non-
toric group (Table 4).Manifest Refractive CylinderThe toric 1.25 D group (n Z 74) had a statistically
significantly lower mean absolute residual cylinder
than the nontoric group (nZ 68) (0.48G 0.41 D versus
0.89G 0.61 D) (Figure 4). The difference between the 2
groups was 0.41G 0.52 D (P! .001).Corneal Cylinder Versus Manifest Refractive
CylinderFigure 4 compares the magnitude of corneal
cylinder (via keratometry) at the 120- to 180-day visit
with the magnitude of residual refractive cylinder aterative visit.
P Value Control
Vs Toric 1.25 D
All Toric
(nZ 134)
P Value Control
Vs All Toric
.002 !.001
20/25
0.093G 0.132
.606 .530
20/22
0.042G 0.129
.980
20/39
0.289G 0.150
isual acuity; UNVAZ uncorrected near visual acuity
OL 41, FEBRUARY 2015
Figure 3. The UDVA, UIVA, andUNVA in the all-diopter toric group
at the 120- to 180-day visit (nZ 134) (UDVAZ uncorrected distance
visual acuity; UIVA Z uncorrected intermediate visual acuity;
UNVAZ uncorrected near visual acuity).
Table 4. Mean DCIVA, DCNVA, DCNVA with add and the
mean add at the 120- to 180-day postoperative visit.
Parameter Toric Control All Toric
P
Value
DCIVA .594
Eyes (n) 67 133
Mean Snellen 20/24 20/23
Mean logMARG SD 0.074G 0.142 0.054G 0.125
DCNVA .756
Eyes (n) 67 133
Mean Snellen 20/41 20/40
Mean logMARG SD 0.309G 0.138 0.301G 0.144
DCNVA with add .310
Eyes (n) 68 134
Mean Snellen 20/22 20/22
Mean logMARG SD 0.045G 0.072 0.036G 0.072
Mean addG SD 1.599G 0.575 1.448G 0.486 .051
addZ addition; DCIVAZ distance-corrected intermediate visual acuity;
DCNVAZ distance-corrected near visual acuity
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qualifying for the lowest toric cohort were randomized
1:1 between the nontoric group and the 1.25 D toric
IOL, their mean corneal cylinder was the same
(1.14G 0.41 D and 1.16G 0.43 D, respectively). How-
ever, the residual manifest refractive was statistically
significantly lower with the 1.25 D toric IOL than
with the nontoric IOL (0.48 G 0.41 D versus
0.89G 0.61 D). Eyes with the 2.00 D and 2.75 D toric
IOLs had equivalent higher corneal astigmatism
(1.60G 0.48 D and 2.07G 0.55 D, respectively); how-
ever, the mean manifest refractive cylinder remainedFigure 4. Mean magnitude of corneal cylinder versus manifest
refractive cylinder at the 120- to 180-day visit.
J CATARACT REFRACT SURG - Vless than 0.50 D (0.43 G 0.50 D and 0.32 G 0.38 D,
respectively).Manifest Refractive Spherical EquivalentAt the 120- to 180-day visit, the mean MRSE in the
134 eyes in the all-diopter toric group was
0.29 G 0.49 D; the MRSE was within G0.50 D in
100 eyes (74.6%) and within G1.00 D in 126 eyes
(94.0%). At the 120- to 180-day visit, the mean MRSE
in the 68 eyes in nontoric group was 0.45G 0.56 D;
the MRSE was within G0.50 D in 42 eyes (61.8%)
and withinG1.00 D in 61 eyes (89.7%). The 0.16 D dif-
ference in the mean MRSE between the all-diopter
toric group and the nontoric group and was statisti-
cally significant (PZ .03).Surgically Induced AstigmatismThemean SIAwas 0.748G 0.492 D in the all-diopter
toric group and 0.696G 0.467 D in the nontoric group.Rotational StabilityTable 5 shows the mean absolute IOL rotation be-
tween implantation and the 120- to 180-day visit. As
shown, 123 of 128 patients (96.1%) in the all-diopter
toric group had 5 degrees or less of absolute rotation
from immediately after implantation to the 120- to
180-day visit.Visual DisturbancesOne patient (0.8%) with a 2.00 D toric IOL and 6 pa-
tients (9.1%) with a nontoric IOL reported having 1 or
more significant visual disturbances. In the 1 patientOL 41, FEBRUARY 2015
Table 5. Absolute rotation between implantation and the 120- to 180-day visit.
Rotation Toric 1.25 D (nZ 72) Toric 2.00 D (nZ 36) Toric 1.75 D (nZ 20) All Toric (nZ 128)
MeanG SD (degrees) 2.2G 3.7 1.4G 1.1 1.4G 1.3 1.9G 2.9
%5.00, eyes (%) 67 (93.1) 36 (100.0) 20 (100.0) 123 (96.1)
5.01 to 10.00, eyes (%) 4 (5.6) 0 0 4 (3.1)
O10.00, eyes (%) 1 (1.4) 0 0 1 (0.8)
301SAFETY AND EFFECTIVENESS OF A NEW TORIC PRESBYOPIA-CORRECTING PC SILICONE IOLwith the 2.00 D toric IOL, the IOL was 1.43 degrees
from its target axis orientation at the 120- to 180-day
visit. The patient developed moderate posterior
capsule opacification (PCO). After a neodymium:YAG
(Nd:YAG) treatment, the patient reported that the
visual disturbances were resolved. None of the pa-
tients (20 eyes with the highest cylinder correction
[2.75 D]) reported significant visual disturbances.Intraocular Lens Decentration and TiltThe mean total decentration at the 120- to 180-day
visit was 0.007 G 0.086 mm (range 0.00 to 1.00 mm)
in the all-diopter toric group and 0.001 G 0.012 mm
(range 0.00 to 0.10 mm) in the nontoric group. The
mean IOL tilt was 0.285 G 1.083 degrees (range 0.00
to 8.74 degrees) in the all-diopter toric group and
0.362 G 1.026 degrees (range 0.00 to 5.83 degrees) in
the nontoric group. The mean difference in IOL tilt
(0.077G 1.065 degrees) between the all-diopter toric
group and the nontoric group was not statistically sig-
nificant (PZ .628; 95% CI, 0.392 to 0.237). The 1 eye
with 8.74 degrees of tilt had a UDVA and CDVA
of 20/20 and no visual disturbances at the 120- to
180-day visit. At subsequent visits, this IOL was tilted
1.94 degrees.SafetyThe safety analysis included 227 eyes of 229 pa-
tients. The CDVA was 20/40 or better in 148 (98.0%)
of 151 eyes in the all-diopter toric group and in all 76
eyes in the nontoric group. In both groups, the percent-
age exceeded the FDA grid rate of 92.5%.
The cumulative adverse events through the 120- to
180-day visit were 1 case (0.7%) of macular edema
and 1 case (0.7%) of secondary surgical intervention
in the all-diopter toric group and 1 case (1.3%) of mac-
ular edema and 2 cases (2.6%) of secondary surgical in-
terventions in the nontoric group. These rates were not
statistically significantly different from the FDA grid
rates (3.0% for macular edema; 0.8% for secondary
surgical intervention). The secondary surgical inter-
vention in the toric IOL group was IOL repositioning
that was not related to lens axis misalignment or
rotation.J CATARACT REFRACT SURG - VAdverse ocular events occurred in 69 eyes (45.7%) in
the toric group and 38 eyes (50.0%) in the nontoric
group. The most prevalent adverse events in the eye
disorders category were dry eye (all-diopter toric
group, 13 eyes [8.6]; nontoric group, 3 eyes [3.9%])
and vitreous detachment (10 eyes [6.6%] and 5 eyes
[6.6%], respectively).
Four serious adverse events related to an ocular
finding occurred. They were IOLmalposition (1 haptic
in and 1 outside the capsular bag) (nontoric group),
anterior vault (toric group), anterior optic capture
(nontoric group), and optic neuropathy (toric group).
At the 120- to 180-day visit, 149 (98.6%) of 151 eyes
in the toric group and 75 (98.6%) of 76 eyes in the non-
toric group had a PCO grade of 2 or less. Fifty-one eyes
(33.8%) and 33 eyes (43.4%), respectively, required an
Nd:YAG capsulotomy during the study. No complica-
tions were associated with the capsulotomy.DISCUSSION
The findings in this study show the safety and effec-
tiveness of the Trulign toric IOL. The data at the rota-
tional stability time point (120 to 180 days) support
the effectiveness of the toric IOL, as shown by the
85.0% reduction in absolute cylinder and excellent
rotational stability (96.1% with %5 degrees between
implantation and visit 4 and 100% with 5 degrees or
less between visit 3 and visit 4). The toric IOL group
had statistically significantly greater reduction in abso-
lute cylinder and better UDVA than the nontoric IOL
group. Subjective reports of significant visual distur-
bances were limited to a single case in which a 2.00 D
toric IOL was implanted; the symptoms resolved after
Nd:YAG treatment for PCO. No patient with the high-
est available cylinder (2.75 D) reported significant vi-
sual disturbances at the 120- to 180-day visit. The
safety endpoints for preservation of CDVA and inci-
dence of adverse events were met.
The effectiveness of a toric IOL in decreasing resid-
ual postoperative astigmatism can decrease when
there is significant IOL rotation. As such, rotational
stability is an important endpoint when evaluating
the performance of a toric IOL. Postoperative refrac-
tion can differ from the predicted refraction when aOL 41, FEBRUARY 2015
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decreases as the toric IOL deviates off axis.17 Each 10
degrees of off-axis rotation results in a loss of one third
(33.3%) of cylinder correction effectiveness.7 For
example, when the IOL rotates 30 degrees or more,
the cylinder correction is lost.18 When the IOL rotates
45 degrees or more, additional cylinder is induced.19
Accordingly, the American National Standards Insti-
tute guidelines state that stability of the toric IOL
axis is achieved when 90% of the implanted IOLs
rotate 5 degrees or less between 2 consecutive visits
at least 3 months apart.16 In the present study, the
degree of rotation of all toric IOLs was 5 degrees or
less between the 30- to 60-day visit and the 120- to
180-day visit.
However, it has been shown that the greatest risk for
rotation of toric IOLs of all designs is in the early post-
operative period. Hence, it is important to assess the
rotational stability of a toric IOLduring this timeframe.
Furthermore, anymethod used to assess rotational sta-
bility should be objective and should account for the
natural torsion of the eye that occurs betweenmeasure-
ments. With this in mind, we began recording the rota-
tional stability of the IOLs immediately after
implantation using an image-analysis technique that
accounts for eye torsion. Using this method, we found
that by the 120- to 180-day visit, 96.1% of IOLs in the
all-diopter toric group had rotated 5 degrees or less
compared with their position immediately after sur-
gery. The following is the reported rotation of other
toric IOLs models: Tecnis 1-piece (Abbott Medical
Optics, Inc.), 83.9% and 93.9% with 5 degrees or less at
1 to 2months20 eyes at 6 monthsC and 100%with 10 de-
grees or less at 2 months21; A4203 TL (Staar Surgical
Co.), 72% with 5 degrees or less at 1 month22; Acrysof
(Alcon Laboratories, Inc.) 75% to 85% of IOLswith 5 de-
grees or less at 120 to 180 days,D 78% with 5 degrees or
less at 1 year,23 and 100% with less than 10 degrees at
2 months21; Acrysof Restor multifocal (SND1T2-T5),
100% with 10 degrees or less at 3 months.24
Polyimide loops added to silicone haptics increase
the stability of an IOL in the capsular bag.25 This might
explain whywe found less rotation of the Trulign toric
IOL than that reported for other toric IOL models.
Furthermore, the size of the IOL relative to the
capsular bag diameter is important for stability
because a shorter length might allow more rotation
before the capsular bag shrinks.22
Axis deviations with any toric IOL can result from
inaccurate marking of the steep axis, inaccurate orien-
tation of the lens axis at the time of surgery, an unex-
pected surgically induced change in corneal power
and curvature, or physical rotation of the IOL after im-
plantation. Tominimize this effect, the surgeon should
be careful to ensure that preoperative determinationsJ CATARACT REFRACT SURG - Vof the meridian in which the IOL is placed are accurate
and not affected by surgery and that the IOL is prop-
erly oriented at surgery (ie, placed on the appropriate
axis in accordance with vector analysis provided by a
toric calculator). The design of the Trulign toric IOL
might contribute to its rotational stability. The IOL
has rectangular, hinged haptics with polyimide loops
that help to stabilize the IOL in the capsular bag and
has indicators to remind the surgeon that it is round
to the right, which facilitates proper IOL positioning.
The differences in UDVA between the lowest toric
group and the nontoric group, while statistically sig-
nificant, were small. However, in general, patients
report less satisfaction when the UDVA is 20/30
than when it is 20/25. In our study, the incision was
created along the steepest axis in both the toric group
and the nontoric (control) group. Thus, some reduc-
tion in astigmatism, even in the control group, was
expected. All surgeons used the same SIA value,
regardless of the incision location andwithout custom-
ization. In addition, no effort was made to determine
posterior corneal astigmatism for use in the surgical
planning. This could have affected the outcomes by
introducing more noise-to-signal in determining the
optimum toric IOL alignment or power. Ultimately,
this would have a greater relative impact in eyes
with lower preexisting corneal toricity. These limita-
tions and potential sources of error are inherent to all
toric IOLs and might be mitigated by customization
of the SIA and A-constant, the use of Scheimpflug sys-
tems that measure both anterior and posterior corneal
astigmatism, and the use of intraoperative aberrome-
try for additional surgical guidance.
In addition to toric IOL implantation, surgical
options for patients with preexisting corneal astigma-
tism include corneal arcuate and peripheral corneal re-
laxing incisions and excimer laser vision correction.
Potential complications of incisional surgery that are
not present with toric IOLs include wound gape and
the associated infection, corneal deinnervation exacer-
bating dry eye, epithelial cysts and ingrowth into the
incisions, and occasional corneal perforation.26 Vari-
ability in corneal biomechanics and wound healing
might, in part, explain the recent findings in a study
by Hirnschall et al.,27 in which toric IOLs reduced
astigmatism to a greater extent and were more
predictable and stable than peripheral corneal relaxing
incisions. Laser in situ keratomileusis and photo-
refractive keratectomy to reduce corneal astigmatism
might be associated with a high incidence of dry eye
and fluctuating vision in this demographic, which
is already at higher risk for dry eye preoperatively.28
It also involves a second surgical procedure, unlike
the single procedure of toric IOL placement during
cataract surgery.OL 41, FEBRUARY 2015
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required for intermediate and near tasks because
monofocal IOLs that do not correct presbyopia do
not adequately improve intermediate and near vision.
At near (30 to 40 cm), the Acrysof SN60WF IOL (Alcon
Laboratories, Inc.) and CeeOn 911A IOL (Abbott Med-
ical Optics, Inc.) were reported to provide a mean
DCNVA of 20/100 and 20/72, respectively.29,30 In
comparison, the all-diopter toric group had a mean
DCNVA of 20/40. At intermediate (70 to 80 cm) dis-
tances, the Acrysof SN60WF and CeeOn 911Awere re-
ported to provide a DCIVA of 20/40 and 20/38,
respectively.29,30 In comparison, the all-diopter toric
group had a mean DCIVA of 20/23dclose to double
that of the monofocal IOLs that do not correct pres-
byopia. These acuities were measured with optimum
distance correction; thus, the improved near and inter-
mediate acuities were not a reflection of the residual
refractive error but rather of the inherent attributes
of the IOL. In addition, the better dynamic through-
focus at intermediate and near with the Trulign toric
IOL and the Crystalens IOL than with monofocal
IOLs that do not correct presbyopia is reflected in the
lower required add (w1.5 D versus 2.5 D).29,30
The all-diopter toric group had a mean UDVA of
20/25. At the 120- to 180-day visit, 97.8% in the all-
diopter toric group had UDVA of 20/40 or better.
Studies report that the UDVA was 20/40 in 48% to
84% of patients with the AA4203 T toric silicone IOL
at various time points17,31,32 and 93.3% of patients
with the Acrysof toric IOL had a UDVA of 20/40 at
3 months33 and 92.2% at 1 year.23 In a study of the
Tecnis toric IOL (ZCT150, ZCT225, ZCT300, and
ZCT400),C 97.1% of 172 eyes in the pooled Tecnis toric
IOL group had aUDVA of 20/40 or better at 6months;
the mean UDVA was 20/26. In a smaller study of 20
eyes with the Tecnis toric IOL,21 the mean UDVA
was 20/26 at 2 months; all eyes had a UDVA of
20/40 or better. The mean UDVA, UIVA, and UNVA
in the all-diopter toric group was 20/25, 20/22, and
20/39, respectively, when implanted monocularly, as
per this study design, which is without the additional
benefit of binocular summation on visual acuity. These
comparisons show that the Trulign toric IOL provides
excellent uncorrected distance acuity, better interme-
diate visual acuity, and functional uncorrected near
vision.
The safety endpoints for preservation of CDVA and
incidence of complications and adverse events were
met. The rate of FDA-defined cumulative adverse
events through the 120- to 180-day visit were not sta-
tistically significantly above FDA historical control
rates. Ocular adverse events were of the type and
frequency typically seen in patients who had cataract
surgery; there were no new safety concerns. ThereJ CATARACT REFRACT SURG - Vwere specific serious ocular adverse events, which
provides insight and guidance into appropriate rec-
ommendations for directions for use. For example,
the serious adverse event of IOL malpositioning with
1 haptic in the bag and the other in the sulcus is com-
mon to all IOL types. Rotating the IOL after insertion
will help ensure that both haptics are in the capsular
bag. The serious adverse event of anterior vault could,
in part, be attributed to the patient's noncompliance
with postoperative antiinflammatory medication,
which can result in atypical fibrosis of the capsular
bag. This fibrosis could lead to significant capsule
contraction, which caused the study device to vault
in an anterior position, given the ability of this hinged
IOL to change position of the optic. Preemptive
Nd:YAG treatment at the first sign of capsule striae
was not performed in this study and is recommended.
The fellow eye of this patient also had early capsule
striae, which were treated with an Nd:YAG laser at
2 months with no subsequent IOL vault. This case
also illustrates the importance of maintaining patients
on antiinflammatory medications for a minimum of
4 weeks.
In our study, the serious adverse event of anterior
optic capture occurred 6 months after implantation
of the nontoric IOL in a patient who reported blurry,
distorted vision. The investigator noted that the IOL
optic was captured superiorly in the anterior capsule.
This patient was lost to follow-up before a scheduled
Nd:YAG capsulotomy was performed. The anterior
optic capture could be attributed to atypical fibrosis
of the capsular bag or to the creation of a decentered
or irregularly shaped capsulorhexis. As described in
the directions for use of the Crystalens,E it is important
to perform meticulous cortical cleanup and create a
round, well-centered 5.5 to 6.0 mm capsulorhexis
with the anterior capsule covering the plate haptics.
Selective Nd:YAG capsulotomy has been beneficial
in managing cases such because it counteracts the ef-
fect of atypical capsule contraction and constriction
and allows the IOL to be repositioned in the appro-
priate posteriorly vaulted position.
Strengths of this clinical trial are its prospective ran-
domized single-masked design and the objective
assessment of IOL rotational stability using photo-
graphic documentation and evaluation by an indepen-
dent, third-party consultant. Limitations of the study
are that long-term data are not available at this time,
the effectiveness of the AT-52T model was not
assessed independent of the AT-50T model, and
spectacle independence could not be measured
because the Trulign toric IOL was not implanted
binocularly in any case.
In conclusion, the Trulign toric IOL reduced the ef-
fects of preoperative corneal astigmatism on refractionOL 41, FEBRUARY 2015
304 SAFETY AND EFFECTIVENESS OF A NEW TORIC PRESBYOPIA-CORRECTING PC SILICONE IOLafter cataract surgery and provided improved dis-
tance, intermediate, and functional near vision. The re-
sults show that the Trulign toric IOL is effective in
reducing refractive cylinder in patients with both
lower and higher magnitudes of preexisting corneal
astigmatism. Addition of the toric component to the
IOL did not produce new safety concerns. This toric
IOL met all safety and effectiveness endpoints. The
outcomes were dependent on precise biometry
and meticulous surgical technique, including stan-
dardized capsulorhexis size and centration, fastidious
cortical and capsular bag cleaning, and proper IOL
positioning.WHAT WAS KNOWN
 The visual outcomes after cataract surgery with implanta-
tion of standard IOLs that correct spherical error only can
be improved if the effect of preexisting corneal astigma-
tism is surgically addressed.WHAT THIS PAPER ADDS
 The safety and efficacy of a new monofocal presbyopia-
correcting toric IOL was confirmed.
 The toric IOL reduced the refractive effects of preexisting
corneal astigmatism and improved through-focus.
 The toric IOL provided excellent uncorrected distance and
intermediate vision and functional near vision in a single
procedure.
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